These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bortezomib and its role in the management of patients with multiple myeloma. Orlowski RZ Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047 [TBL] [Abstract][Full Text] [Related]
4. The proteasome and proteasome inhibitors in cancer therapy. Voorhees PM; Orlowski RZ Annu Rev Pharmacol Toxicol; 2006; 46():189-213. PubMed ID: 16402903 [TBL] [Abstract][Full Text] [Related]
5. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388 [TBL] [Abstract][Full Text] [Related]
7. Targeting the ubiquitin-proteasome pathway in cancer therapy. Ishii Y; Waxman S; Germain D Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161 [TBL] [Abstract][Full Text] [Related]
8. Bortezomib in multiple myeloma. Mateos MV; San Miguel JF Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714 [TBL] [Abstract][Full Text] [Related]
9. The proteasome: a novel target for anticancer therapy. Montagut C; Rovira A; Albanell J Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005 [TBL] [Abstract][Full Text] [Related]
10. Novel proteasome inhibitors to overcome bortezomib resistance. Ruschak AM; Slassi M; Kay LE; Schimmer AD J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441 [TBL] [Abstract][Full Text] [Related]
11. Update on the proteasome inhibitor bortezomib in hematologic malignancies. Goy A; Gilles F Clin Lymphoma; 2004 Mar; 4(4):230-7. PubMed ID: 15072615 [TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Leonard JP; Furman RR; Coleman M Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600 [TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Ludwig H; Khayat D; Giaccone G; Facon T Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003 [TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors. Cheriyath V; Jacobs BS; Hussein MA Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845 [TBL] [Abstract][Full Text] [Related]
15. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Dou QP; Zonder JA Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212 [TBL] [Abstract][Full Text] [Related]
16. [Classification and synthesis of ubiquitin-proteasome inhibitor]. Li J; Zhang DY; Wu XM Yao Xue Xue Bao; 2009 Dec; 44(12):1313-9. PubMed ID: 21351462 [TBL] [Abstract][Full Text] [Related]
18. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071 [TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment. Montagut C; Rovira A; Mellado B; Gascon P; Ross JS; Albanell J Drugs Today (Barc); 2005 May; 41(5):299-315. PubMed ID: 16082428 [TBL] [Abstract][Full Text] [Related]
20. An analysis of the safety profile of proteasome inhibitors for treating various cancers. Wang H; Guan F; Chen D; Dou QP; Yang H Expert Opin Drug Saf; 2014 Aug; 13(8):1043-54. PubMed ID: 25005844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]